-- Days : -- HRS : -- MIN : -- SEC

Register Now →

News
Watch
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

Opinion|Videos|June 11, 2024

Key Treatment Considerations for Patients Diagnosed With PNH

Dr Haumschild drives a discussion surrounding impactful PNH treatment strategies.

Episodes in this series

EP. 1 PNH Overview and Pathophysiology

EP. 1 PNH Overview and Pathophysiology

EP. 2 Intravascular and Extravascular Hemolysis MoA in PNH

EP. 2 Intravascular and Extravascular Hemolysis MoA in PNH

EP. 3 Utilizing Health Information Technology to Bridge Gaps in PNH Treatment Programming

EP. 3 Utilizing Health Information Technology to Bridge Gaps in PNH Treatment Programming

EP. 4 Key Treatment Considerations for Patients Diagnosed With PNH

EP. 4 Key Treatment Considerations for Patients Diagnosed With PNH

EP. 5 Complement System Role in PNH Treatment Approach

EP. 5 Complement System Role in PNH Treatment Approach

EP. 6 Eculizumab Impact on PNH Treatment Landscape and Unmet Needs in PNH Management

EP. 6 Eculizumab Impact on PNH Treatment Landscape and Unmet Needs in PNH Management

EP. 7 Efficacy End Points For PNH Treatment

EP. 7 Efficacy End Points For PNH Treatment

EP. 8 Efficacy and Safety Trials Results of Complement Inhibitors

EP. 8 Efficacy and Safety Trials Results of Complement Inhibitors

EP. 9 Treatment Adherence and Cost Considerations Surrounding Various Routes of PNH Treatment Administration

EP. 9 Treatment Adherence and Cost Considerations Surrounding Various Routes of PNH Treatment Administration

EP. 10 Investigational Therapies Paving New PNH Treatment Pathways

EP. 10 Investigational Therapies Paving New PNH Treatment Pathways

EP. 11 Key Financial Factors Associated With Typical PNH Treatment Journey

EP. 11 Key Financial Factors Associated With Typical PNH Treatment Journey

EP. 12 Navigating Transfusion Requirements in PNH Treatment

EP. 12 Navigating Transfusion Requirements in PNH Treatment

EP. 13 Considerations for Managing PNH Treatment Complications

EP. 13 Considerations for Managing PNH Treatment Complications

EP. 14 Infection Risk Management Counseling For Patients Receiving Treatment for PNH

EP. 14 Infection Risk Management Counseling For Patients Receiving Treatment for PNH

A panel of 4 experts on PNH

EP. 15 Ensuring PNH Treatment Access and Adherence to Therapies

A panel of 4 experts on PNH

EP. 16 Financial Considerations Influencing Treatment Strategies in PNH Treatment Pathway

Video content above is prompted by the following:

What are the goals and primary considerations in developing a treatment plan for patients with paroxysmal nocturnal hemoglobinuria?

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

Vitamin D3 | Image Credit: Adisak - stock.adobe.com

High-Dose Vitamin D3 Fails to Improve PFS in Phase 3 Metastatic CRC Trial

ByBrooke McCormick

August 6th 2026

Katherine Wilemon, CEO of the Family Heart Foundation

Almost No Public Awareness of Lp(a), Elevated CVD Risk in the US: Katherine Wilemon

ByPearl Steinzor,Katherine Wilemon

August 6th 2026

Eosinophilic esophagitis | Image Credit: syahrir - stock.adobe.com

Patients With MASLD Had More Than 2 Times Higher Odds of Eosinophilic Esophagitis Across Age Groups

ByBrooke McCormick

August 6th 2026

Experts featured in this series.

Translating PFS Data for Patients: How Community Oncologists Communicate Trial Outcomes in RRFL

ByRyan Haumschild, PharmD, MS, MBA, CPEL,Christina Poh, MD,Tara Graff DO, MS

August 6th 2026

Avoiding TNF Cycling: When to Switch Drug Classes in Rheumatoid Arthritis

ByJulia Buchfuhrer, DO

August 6th 2026

Trending on AJMC

FDA Approves Moderna’s mRNA Flu Vaccine After Phase 3 Success

Patients With MASLD Had More Than 2 Times Higher Odds of Eosinophilic Esophagitis Across Age Groups

High-Dose Vitamin D3 Fails to Improve PFS in Phase 3 Metastatic CRC Trial

AHA Proposes Staging System for Pediatric Cardiogenic Shock

Remote Monitoring and Self-Efficacy: Implications for Breast Cancer Survivorship Outcomes